Zimmer Biomet (NYSE:ZBH) Hits New 12-Month Low – Should You Sell?

30 Jan 2026, 19:14 by Amy Steele · The Cerbat Gem

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report)’s share price reached a new 52-week low on Wednesday . The company traded as low as $84.91 and last traded at $85.6350, with a volume of 380833 shares traded. The stock had previously closed at $85.99.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday. Canaccord Genuity Group dropped their target price on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. Barclays lowered their target price on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research note on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $107.24.

Read Our Latest Report on Zimmer Biomet

Zimmer Biomet Price Performance

The company has a 50 day simple moving average of $91.11 and a 200-day simple moving average of $96.01. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. The stock has a market cap of $17.25 billion, a price-to-earnings ratio of 21.54, a PEG ratio of 2.19 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the prior year, the firm earned $1.74 EPS. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Institutional Trading of Zimmer Biomet

A number of large investors have recently modified their holdings of the company. Key Financial Inc boosted its stake in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC grew its holdings in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares in the last quarter. Finally, Flagship Harbor Advisors LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.